181 related articles for article (PubMed ID: 25098433)
41. Primary neuroendocrine carcinomas of the breast and neuroendocrine differentiated breast cancers: Relationship between histopathological and radiological features.
Kayadibi Y; Erginoz E; Cavus GH; Kurt SA; Ozturk T; Velidedeoglu M
Eur J Radiol; 2022 Feb; 147():110148. PubMed ID: 35007984
[TBL] [Abstract][Full Text] [Related]
42. [Neuroendocrine carcinoma of the breast: a rare entity].
Sartori A; Scomersi S; Spivach A; Vigna S
Chir Ital; 2009; 61(2):265-7. PubMed ID: 19537005
[TBL] [Abstract][Full Text] [Related]
43. Neuroendocrine differentiation and prognosis in breast adenocarcinoma.
Miremadi A; Pinder SE; Lee AH; Bell JA; Paish EC; Wencyk P; Elston CW; Nicholson RI; Blamey RW; Robertson JF; Ellis IO
Histopathology; 2002 Mar; 40(3):215-22. PubMed ID: 11895486
[TBL] [Abstract][Full Text] [Related]
44. Search for neuro-endocrine markers (chromogranin A, synaptophysin and VGF) in breast cancers. An integrated approach using immunohistochemistry and gene expression profiling.
Annaratone L; Medico E; Rangel N; Castellano I; Marchiò C; Sapino A; Bussolati G
Endocr Pathol; 2014 Sep; 25(3):219-28. PubMed ID: 24277232
[TBL] [Abstract][Full Text] [Related]
45. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.
Leblebici C; Yeni B; Savli TC; Aydın Ö; Güneş P; Cinel L; Şimşek BÇ; Yıldız P; Tuncel D; Kayahan S
Ann Diagn Pathol; 2019 Jun; 40():53-58. PubMed ID: 31031215
[TBL] [Abstract][Full Text] [Related]
46. Management of neuroendocrine differentiated breast carcinoma.
Berruti A; Saini A; Leonardo E; Cappia S; Borasio P; Dogliotti L
Breast; 2004 Dec; 13(6):527-9. PubMed ID: 15563864
[TBL] [Abstract][Full Text] [Related]
47. [Spindle cell carcinoma of breast with neuroendocrine differentiation].
Ding HY; Gao LX
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):13-7. PubMed ID: 16608642
[TBL] [Abstract][Full Text] [Related]
48. Primary small cell carcinoma of the breast: a case report.
Abou Dalle I; Abbas J; Boulos F; Salem Z; Assi HI
J Med Case Rep; 2017 Oct; 11(1):290. PubMed ID: 29047418
[TBL] [Abstract][Full Text] [Related]
49. Neuroendocrine carcinoma of the breast: a review of 126 cases in China.
Li Y; Du F; Zhu W; Xu B
Chin J Cancer; 2017 May; 36(1):45. PubMed ID: 28490384
[No Abstract] [Full Text] [Related]
50. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
51. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
52. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
53. [Clinicopathologic features of combined hepatic carcinoma].
He C; Yin HF; Liu P; Zhang Y; Zhang JB
Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):824-8. PubMed ID: 24507101
[TBL] [Abstract][Full Text] [Related]
54. Neuroendocrine differentiation in carcinoma of the breast. Tyramide signal amplification discloses chromogranin A-positive tumour cells in more breast tumours than previously realized.
Bofin AM; Qvigstad G; Waldum C; Waldum HL
APMIS; 2002 Sep; 110(9):658-64. PubMed ID: 12529020
[TBL] [Abstract][Full Text] [Related]
55. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges.
Tang F; Wei B; Tian Z; Gilcrease MZ; Huo L; Albarracin CT; Resetkova E; Zhang H; Sahin A; Chen J; Bu H; Abraham S; Wu Y
Histopathology; 2011 Jul; 59(1):106-15. PubMed ID: 21668471
[TBL] [Abstract][Full Text] [Related]
56. Case of breast cancer with endocrine differentiation.
Tanaka N; Katayama K; Negishi T; Kano H; Uchida N; Kuwano H
Int Surg; 2007; 92(4):214-7. PubMed ID: 18050830
[TBL] [Abstract][Full Text] [Related]
57. Ovarian neuroendocrine carcinoma of metastatic origin: clues for diagnosis.
Karpathiou G; Matias-Guiu X; Mobarki M; Vermesch C; Stachowicz ML; Chauleur C; Peoc'h M
Hum Pathol; 2019 Mar; 85():309-312. PubMed ID: 30171991
[TBL] [Abstract][Full Text] [Related]
58. Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
Zhou HH; Liu LY; Yu GH; Qu GM; Gong PY; Yu X; Yang P
Anticancer Res; 2017 Aug; 37(8):4529-4537. PubMed ID: 28739749
[TBL] [Abstract][Full Text] [Related]
59. Primary Breast Neuroendocrine Tumor.
Jones VM; Cairns A; Chiba A; Howard-McNatt M
Am Surg; 2022 Aug; 88(8):1898-1900. PubMed ID: 35333626
[TBL] [Abstract][Full Text] [Related]
60. Neuroendocrine carcinoma of the breast - a pilot study of a Danish population of 240 breast cancer patients.
Brask JB; Talman ML; Wielenga VT
APMIS; 2014 Jul; 122(7):585-92. PubMed ID: 24320610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
